Physician profile
Mandy Neblett
NPI 1063789568
$1,639.17
in general payments reported to CMS, 2019-2025
23 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $306 · 2023: $304 · 2024: $435 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $381.73 | 2021-2025 | Entrada, Click, General - Pain Management |
| Collegium Pharmaceutical, INC. | $324.31 | 2021-2025 | Belbuca, Xtampza |
| Nalu Medical, INC. | $149.92 | 2024-2025 | Nalu Neurostimulation System |
| Protega Pharmaceutials INC | $130.09 | 2023-2024 | Roxybond |
| Abbott Laboratories | $75.54 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.81 | 2024-2025 | Relistor |
| Averitas Pharma INC. | $70.05 | 2023-2025 | Qutenza |
| Hikma Pharmaceuticals USA | $61.02 | 2021-2022 | |
| Amgen INC. | $48.28 | 2022 | |
| Grt US Holding, INC. | $45.00 | 2022 | |
| Valinor Pharma, LLC | $44.23 | 2023 | Movantik |
| Abbvie INC. | $43.97 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $25.56 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $24.43 | 2025 | |
| Otto Bock Healthcare LP | $22.02 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $20.52 | 2025 | Tonmya |
| Bioventus LLC | $17.67 | 2024 | Gelsyn-3 |
| Acadia Pharmaceuticals INC | $16.56 | 2024 | Daybue |
| Avanos Medical | $15.38 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Scilex Pharmaceuticals INC. | $13.98 | 2023 | Ztlido |
| Redhill Biopharma INC. | $13.47 | 2021 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Alfasigma USA, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Neblett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.